Aptevo Therapeutics (NASDAQ:APVO) Earns Hold Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Get Rating) in a report issued on Friday. The firm set a “hold” rating on the biotechnology company’s stock.

Aptevo Therapeutics Stock Down 3.0 %

APVO stock opened at $1.63 on Friday. The firm’s 50-day simple moving average is $1.81 and its 200 day simple moving average is $2.22. Aptevo Therapeutics has a fifty-two week low of $1.53 and a fifty-two week high of $7.20.

Aptevo Therapeutics (NASDAQ:APVO – Get Rating) last announced its earnings results on Thursday, May 11th. The biotechnology company reported $0.26 EPS for the quarter, topping the consensus estimate of ($1.19) by $1.45. As a group, analysts forecast that Aptevo Therapeutics will post -3.24 EPS for the current fiscal year.

Institutional Trading of Aptevo Therapeutics

A number of institutional investors have recently added to or reduced their stakes in APVO. Dimensional Fund Advisors LP acquired a new stake in Aptevo Therapeutics in the fourth quarter valued at approximately $29,000. Virtu Financial LLC acquired a new stake in shares of Aptevo Therapeutics in the 2nd quarter valued at $46,000. Citadel Advisors LLC acquired a new stake in shares of Aptevo Therapeutics in the 3rd quarter valued at $51,000. Bank of Montreal Can acquired a new stake in shares of Aptevo Therapeutics in the 4th quarter valued at $61,000. Finally, Bank of New York Mellon Corp acquired a new position in Aptevo Therapeutics during the 1st quarter worth about $152,000. 17.04% of the stock is currently owned by institutional investors and hedge funds.

Aptevo Therapeutics Company Profile

(Get Rating)

Aptevo Therapeutics, Inc is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology.